PTC Therapeutics, Inc. (NASDAQ:PTCT) will report its next earnings on Nov 7 – Nov 11 (Est.). The company reported the earnings of $-1.14/Share in the last quarter where the estimated EPS by analysts was $-1.27/share. The difference between the expected and actual EPS was $0.13/share, which represents an Earnings surprise of 10.2%.

Many analysts are providing their Estimated Earnings analysis for PTC Therapeutics, Inc. and for the current quarter 7 analysts have projected that the stock could give an Average Earnings estimate of $-1.22/share. These analysts have also projected a Low Estimate of $-1.39/share and a High Estimate of $-1.02/share.

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for PTC Therapeutics, Inc. as 19.76 Million. According to these analysts, the Low Revenue Estimate for PTC Therapeutics, Inc. is 13.8 Million and the High Revenue Estimate is 26.75 Million. The company had Year Ago Sales of 9.78 Million.

Some buy side analysts are also providing their Analysis on PTC Therapeutics, Inc., where 0 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 8 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 7 Analysts reported that the Price Target for PTC Therapeutics, Inc. might touch $20 high while the Average Price Target and Low price Target is $11.57 and $5 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. PTC Therapeutics, Inc. got Downgrade on 26-Jul-16 where investment firm Credit Suisse Downgrade the stock from Outperform to Neutral.

PTC Therapeutics, Inc. closed its last trading session at $7.97 with the loss of -5.27%. The Market Capitalization of the company stands at 264.4 Million. The Company has 52-week high of $35.4 and 52-week low of $5.27. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -38.74% where SMA50 and SMA200 are -23.38% and -31.08% respectively. The Company Touched its 52-Week High on Dec 17, 2015 and 52-Week Low on Mar 16, 2016.

The Relative Volume of the company is 5.49 and Average Volume (3 months) is 1.51 million. PTC Therapeutics, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -49.7%. The Return on Equity (ROE) value stands at -81.4%. While it’s Return on Investment (ROI) value is -52.7%.

While looking at the Stock’s Performance, PTC Therapeutics, Inc. currently shows a Weekly Performance of -43.15%, where Monthly Performance is -31.3%, Quarterly performance is 1.89%, 6 Months performance is -0.53% and yearly performance percentage is -74.48%. Year to Date performance value (YTD perf) value is -76.7%. The Stock currently has a Weekly Volatility of 12.96% and Monthly Volatility of 9.91%.